<DOC>
	<DOCNO>NCT00778557</DOCNO>
	<brief_summary>The study conduct blind , randomize , 3-way crossover study compare single-dose relative bioavailability Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder Oral Suspension ( 250 mg/5 mL ) follow one 5 mL dose fasting condition</brief_summary>
	<brief_title>Bioequivalence Study Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions</brief_title>
	<detailed_description>The study design compare rate extent absorption cefprozil follow product fast condition : 1 . CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL ( Ranbaxy Laboratories Limited , India ) 2 . Cefzil TM ( CEFPROZIL ) oral suspension equivalent 250mg/5mL anhydrous , cefprozil ( Bristol-Myers Squibb Company , New Jersey USA ) 3 . Cefzil TM ( CEFPROZIL ) oral suspension equivalent 250mg/5mL anhydrous , cefprozil ( Bristol-Myers Squibb Company , New Jersey USA ) The bioequivalence formulation assess cefprozil . The study follow randomize , 3-way cross , blind single dose , fast design 36 normal healthy , nonsmoking male female subject</detailed_description>
	<mesh_term>Cefprozil</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>1 . Nonsmoking male female minimum age 18 year 2 . Body Mass Index ( BMI= weight/ height ) great equal 18.5 kg/m3 less equal 29.9 kg/m3 3 . Normal finding physical examination , 12 lead ECG vital sign ( blood pressure 100140/6090 mm Hg , heart rate 5090 beats/min , temperature 35.8°C 37.5 °C 4 . Negative drug abuse , nicotine , hepatitis Bsurface antigen , hepatitis C HIV , female subject pregnancy serum ( serum βCG ) 5 . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant 6 . Female subject surgically sterile least 6 month post menopausal one year , avoid pregnancy prior study , study one month end study 7 . Availability subject entire study period willingness adhere protocol requirement evidence sign ICF 1 . Known history hypersensitivity cefprozil ( e.g . Cefzil TM , cephalosporin antibiotic penicillin antibiotic 2 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeltal , neurological , hematological , liver kidney disease , unless judge clinically significant principal investigator Subinvestigator . 3 . Presence significant physical organ abnormality 4 . Any history evidence food allergy 5 . Any subject history drug abuse 6 . Any significant illness 7 . History colitis 8 . Significant recent history Asthma 9 . Any history severe allergic reaction 10 . Any subject recent hi story alcohol abuse 11 . Use prescription medication within 14 day precede study 12 . Use OTC medication within 7 day study 13 . Female subject : use contraceptive ( oral , transdermal , implant , Mirena ® ) within 30 day prior drug administration depot injection progesterone drug ( eg . DepoProvera® ) within one year prior drug administration 14 . Female subject evidence pregnancy lactation 15 . Any subject blood drawn prior study conduct clinic study BCR within lock period specify previous study conduct BCR 16 . Participation clinical trial investigational drug within 30 day precede study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL , Bioequivalence fasting condition</keyword>
</DOC>